Moreover, our study provided a detailed analysis of the expression patterns of FOXP3 in ccRCC and its specific impact on the tumor immune environment, discussing its potential as a therapeutic target. This evidence concerns the gene FOXP3 and nonpapillary renal cell carcinoma.